Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blinded, Randomized, Sham-Controlled, Study of the Revised NeuroPoint Device for the Treatment of Pain Associated With Fibromyalgia

NCT02613949 is registered in ClinicalTrials.gov with Cerephex Corporation as lead sponsor.

NCT NCT02613949
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02613949 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blinded, Randomized, Sham-Controlled, Study of the Revised NeuroPoint Device for the Treatment of Pain Associated With Fibromyalgia
Lead sponsor
Cerephex Corporation
Phase
Not applicable
Overall status
Completed
Start date
November 30, 2015
Completion date
July 29, 2016
Enrollment
45 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

fibromyalgia